Topics
- Page Path
-
- HOME
- TOPICS
- Topics
- Original Article
- Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)
- Chuan Liu, Hong You, Qing-Lei Zeng, Yu Jun Wong, Bingqiong Wang, Ivica Grgurevic, Chenghai Liu, Hyung Joon Yim, Wei Gou, Bingtian Dong, Shenghong Ju, Yanan Guo, Qian Yu, Masashi Hirooka, Hirayuki Enomoto, Amr Shaaban Hanafy, Zhujun Cao, Xiemin Dong, Jing LV, Tae Hyung Kim, Yohei Koizumi, Yoichi Hiasa, Takashi Nishimura, Hiroko Iijima, Chuanjun Xu, Erhei Dai, Xiaoling Lan, Changxiang Lai, Shirong Liu, Fang Wang, Ying Guo, Jiaojian Lv, Liting Zhang, Yuqing Wang, Qing Xie, Chuxiao Shao, Zhensheng Liu, Federico Ravaioli, Antonio Colecchia, Jie Li, Gao-Jun Teng, Xiaolong Qi
- Clin Mol Hepatol. 2025;31(1):105-118. Published online July 11, 2024
-
View: 3720 Download: 329 Web of Science: 5 Crossref: 2
- Review
- Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment
- Atsumasa Komori, Yuki Kugiyama
- Clin Mol Hepatol. 2025;31(1):90-104. Published online November 11, 2024
-
View: 2088 Download: 225 Web of Science: 1 Crossref: 1
- Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations
- Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, Aijaz Ahmed, Karn Wijarnpreecha, Donghee Kim
- Clin Mol Hepatol. 2025;31(1):74-89. Published online October 23, 2024
-
View: 4102 Download: 383 Web of Science: 10 Crossref: 14
- Bioactive metabolites: A clue to the link between MASLD and CKD?
- Wen-Ying Chen, Jia-Hui Zhang, Li-Li Chen, Christopher D. Byrne, Giovanni Targher, Liang Luo, Yan Ni, Ming-Hua Zheng, Dan-Qin Sun
- Clin Mol Hepatol. 2025;31(1):56-73. Published online October 21, 2024
-
View: 2729 Download: 198 Web of Science: 1 Crossref: 2
- Sinusoidal communication in chronic liver disease
- Albert Gibert-Ramos, María Andrés-Rozas, Raül Pastó, Pablo Alfaro-Retamero, Sergi Guixé-Muntet, Jordi Gracia-Sancho
- Clin Mol Hepatol. 2025;31(1):32-55. Published online October 2, 2024
-
View: 2657 Download: 247 Web of Science: 2 Crossref: 1
- Roles of X-box binding protein 1 in liver pathogenesis
- Jihoon Tak, Yun Seok Kim, Sang Geon Kim
- Clin Mol Hepatol. 2025;31(1):1-31. Published online October 2, 2024
-
View: 2832 Download: 181 Web of Science: 1 Crossref: 1
- Correspondence
- Correspondence to editorial on “UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL”
- Renyu Zhang, Ding Wei, Zhinan Chen, Huijie Bian
- Clin Mol Hepatol. 2025;31(1):e58-e60. Published online July 29, 2024
-
View: 1104 Download: 58 Web of Science: 1 Crossref: 1
- Reply to Correspondence
- Reply to correspondence on “UBE2S: A novel driver of HIF-1alpha-induced metabolic reprogramming in hepatocellular carcinoma”
- Martina Mang Leng Lei, Terence Kin Wah Lee
- Clin Mol Hepatol. 2025;31(1):e119-e120. Published online August 5, 2024
-
View: 1050 Download: 40
- Correspondence
- Correspondence to letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”
- Gi-Ae Kim, Seung Won Choi, Young-Suk Lim
- Clin Mol Hepatol. 2025;31(1):e108-e109. Published online August 5, 2024
-
View: 1123 Download: 34
- Letter to the Editor
- Presence of liver fibrosis in chronic hepatitis B patients with varying serum hepatitis B virus DNA levels: Letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”
- Jian Wang, Shaoqiu Zhang, Chuanwu Zhu, Yuanwang Qiu, Chao Wu, Rui Huang
- Clin Mol Hepatol. 2025;31(1):e27-e30. Published online August 7, 2024
-
View: 1215 Download: 52 Crossref: 1
- Correspondence
- Steatotic liver disease in chronic hepatitis C related hepatocellular carcinoma: Inflictor or bystander?: Correspondence to editorial on “Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan”
- Chung-Feng Huang, Ming-Lun Yeh, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu
- Clin Mol Hepatol. 2025;31(1):e64-e66. Published online August 19, 2024
-
View: 1240 Download: 53 Web of Science: 1 Crossref: 1
- Letter to the Editor
- Letter to the editor on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
- Meng-Che Wu, Hui-Chin Chang, Yi-Sheng Jhang, Shuo-Yan Gau
- Clin Mol Hepatol. 2025;31(1):e13-e14. Published online September 2, 2024
-
View: 1363 Download: 104 Crossref: 1
- Correspondence
- PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
- Baokai Sun, Likun Zhuang
- Clin Mol Hepatol. 2025;31(1):e67-e69. Published online September 10, 2024
-
View: 1166 Download: 81
- Correspondence to editorial on “KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression”
- Sang Bae Lee, KyeongJin Kim
- Clin Mol Hepatol. 2025;31(1):e78-e80. Published online September 10, 2024
-
View: 1114 Download: 73
- Correspondence to editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease”
- Amal Magdy, Hee-Jin Kim, Won Kim, Mirang Kim
- Clin Mol Hepatol. 2025;31(1):e70-e73. Published online September 10, 2024
-
View: 1176 Download: 64
- Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”
- Hee Yeon Kim, Miyoung Choi, Dae Won Jun
- Clin Mol Hepatol. 2025;31(1):e48-e51. Published online September 11, 2024
-
View: 1132 Download: 26
- Letter to the Editor
- Letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”
- Xiao-Song Li, Xi-Ping Shen, Hang Li
- Clin Mol Hepatol. 2025;31(1):e15-e16. Published online September 12, 2024
-
View: 1084 Download: 44 Web of Science: 1 Crossref: 1
- Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes
- Meng-Yuan Miao, Jie-Qiong Lyu, Wei Jiang, Zhong-Yue Liu, Guo-Chong Chen
- Clin Mol Hepatol. 2025;31(1):e35-e38. Published online September 20, 2024
-
View: 1302 Download: 74 Web of Science: 1 Crossref: 1
- Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma
- Binghua Li, Jingyuan Wen, Zhu Xu, Peng Yan, Bing Han, Decai Yu
- Clin Mol Hepatol. 2025;31(1):e31-e34. Published online September 20, 2024
-
View: 1378 Download: 110 Crossref: 2
- Correspondence
- Correspondence to letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”
- Yuri Cho, Dae Won Jun
- Clin Mol Hepatol. 2025;31(1):e103-e104. Published online September 24, 2024
-
View: 1063 Download: 37
- Correspondence to editorial on “Optimal cutoffs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”
- Jung Hwan Yu, Seung Up Kim
- Clin Mol Hepatol. 2025;31(1):e52-e54. Published online September 24, 2024
-
View: 1179 Download: 30
- Letter to the Editor
- Accountability in AI medicine: A critical appraisal of ChatGPT in patient self-management and screening
- Jiawen Wang, Tian Xia
- Clin Mol Hepatol. 2025;31(1):e1-e2. Published online September 26, 2024
-
View: 1098 Download: 49
- Correspondence
- Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
- Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Peng Wei, Ju-Seog Lee
- Clin Mol Hepatol. 2025;31(1):e110-e112. Published online October 2, 2024
-
View: 1176 Download: 50
- Correspondence to editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”
- Young-Joo Jin, Seung Up Kim
- Clin Mol Hepatol. 2025;31(1):e55-e57. Published online October 7, 2024
-
View: 1029 Download: 21 Crossref: 1
- Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”
- Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S. Lee, Ahmed O. Kaseb, Ju-Seog Lee
- Clin Mol Hepatol. 2025;31(1):e81-e83. Published online October 7, 2024
-
View: 1194 Download: 36 Crossref: 1
- Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”
- Sun Young Yim, Sung Hwan Lee, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Ju-Seog Lee
- Clin Mol Hepatol. 2025;31(1):e84-e86. Published online October 7, 2024
-
View: 1148 Download: 34
- Letter to the Editor
- Comparison of the therapeutic effects of transarterial radioembolization and tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis
- Hang Li, Hua Lu, Xi-Ping Shen, Xiao-Song Li
- Clin Mol Hepatol. 2025;31(1):e3-e4. Published online October 7, 2024
-
View: 1150 Download: 51 Crossref: 1
- Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults
- Donghee Kim, Won Kim, Aijaz Ahmed
- Clin Mol Hepatol. 2025;31(1):e5-e7. Published online October 8, 2024
-
View: 1090 Download: 43 Web of Science: 1 Crossref: 1
- Reply to Correspondence
- Reply to correspondence on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”
- Antonio Bertoletti, Anthony T Tan
- Clin Mol Hepatol. 2025;31(1):e113-e116. Published online October 11, 2024
-
View: 1218 Download: 33
- Letter to the Editor
- Development of risk scores for prognosis prediction among patients with early-stage hepatocellular carcinoma
- Xiping Shen, Ji Wu
- Clin Mol Hepatol. 2025;31(1):e17-e18. Published online October 11, 2024
-
View: 1177 Download: 49 Crossref: 1
-
Clinical and
Molecular
HepatologyPrint ISSN: 2287-2728
Online ISSN: 2287-285X
-
-
Video abstract
-
- Modulation of lymphatic vessels in management of liver disease and complications
- Metabolic dysfunction-associated steatotic liver disease across women’s reproductive lifespan and issues
- Examining the therapeutic landscape of beta-blockers in portal hypertension
- Immunopathogenesis of liver fibrosis in steatotic liver disease
- Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
- Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease
- The role of the hepatic autonomic nervous system
- HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?
- Systemic therapy in advanced hepatocellular carcinoma
- Epidemiology and updated management for autoimmune liver disease
- Microbiome and metabolomics in alcoholic liver disease
- Personalized medicine in nonalcoholic fatty liver disease
- Acute on chronic liver failure in cirrhosis
- Current status and outcome of liver transplantation in South Korea
- History and future of hepatitis B virus control in South Korea
- Hepatocellular carcinoma statistics in South Korea
Impact Factor16.9First decision
07 Days
Publication after acceptance
04 Days
*Last 12 months
- MOST VIEWED (Last 6 months)
- MOST CITED (2023-2025)
|
|||||||
